KALV has been in the news 1000% more than usual
Dec 05, 2024, 5:31 PM
-7.33%
What does KALV do
KalVista Pharmaceuticals, based in Cambridge, Massachusetts, specializes in small molecule protease inhibitors for unmet medical needs, focusing on hereditary angioedema treatments like sebetralstat and Factor XIIa inhibitors. The company went public in April 2015 and employs 150 staff.
KALV has been in the news recently: KalVista Pharmaceuticals granted five new employees options to purchase a total of 36,000 shares at $10.27 each, with the options vesting over four years. Additionally, the company reported that the FDA accepted its New Drug Application for sebetralstat, targeting a potential market launch by June 17, 2025, for treating hereditary angioedema.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.